(MBB) MBB INDUSTRIES - Overview
Stock: Machinery, Cloud Services, Hardwood Materials, Tissue Products, Mattresses
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.43% |
| Yield on Cost 5y | 2.56% |
| Yield CAGR 5y | 17.28% |
| Payout Consistency | 92.1% |
| Payout Ratio | 31.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 33.4% |
| Relative Tail Risk | -12.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.11 |
| Alpha | 103.48 |
| Character TTM | |
|---|---|
| Beta | 0.168 |
| Beta Downside | 0.242 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.95% |
| CAGR/Max DD | 2.04 |
Description: MBB MBB INDUSTRIES January 21, 2026
MBB SE (XETRA:MBB) is a Berlin-based industrial conglomerate that acquires and runs midsize firms across technology and engineering. It operates three divisions: Service & Infrastructure (IT-security, cloud, and pipeline/plant engineering for gas, power grids and emerging hydrogen networks); Technological Applications (specialty machinery and automated lines for e-mobility, plus eco-friendly hardwood systems for automotive, rail and safety markets); and Consumer Goods (tissue products under the “aha” brand and mattress/pillow manufacturing).
Key recent metrics: FY 2023 reported revenue of €1.2 bn, with an adjusted EBITDA margin of ~9.5%-slightly above the German industrial average of ~8% (source: company release, 2024). The e-mobility machinery segment grew ~14% YoY, reflecting the EU’s 2025 target of 30 million EVs, while hydrogen infrastructure orders rose ~22% as Germany’s “Hydrogen Strategy” allocates €9 bn to expand the gas-to-hydrogen conversion capacity. In the consumer-goods arm, the “aha” tissue line saw a 5% volume increase, driven by steady demand for premium disposable hygiene products in the post-pandemic market.
For a deeper, data-driven view of MBB’s valuation dynamics, you might explore the analyst dashboards on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 54.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.71 > 1.0 |
| NWC/Revenue: 46.21% < 20% (prev 44.10%; Δ 2.11% < -1%) |
| CFO/TA 0.14 > 3% & CFO 181.3m > Net Income 54.2m |
| Net Debt (-246.2m) to EBITDA (202.9m): -1.21 < 3 |
| Current Ratio: 3.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (5.32m) vs 12m ago 0.04% < -2% |
| Gross Margin: 48.95% > 18% (prev 0.28%; Δ 4867 % > 0.5%) |
| Asset Turnover: 95.38% > 50% (prev 88.19%; Δ 7.19% > 0%) |
| Interest Coverage Ratio: 36.49 > 6 (EBITDA TTM 202.9m / Interest Expense TTM 4.18m) |
Altman Z'' 4.47
| A: 0.42 (Total Current Assets 800.1m - Total Current Liabilities 261.3m) / Total Assets 1.28b |
| B: 0.13 (Retained Earnings 169.5m / Total Assets 1.28b) |
| C: 0.12 (EBIT TTM 152.7m / Avg Total Assets 1.22b) |
| D: 0.42 (Book Value of Equity 174.9m / Total Liabilities 421.0m) |
| Altman-Z'' Score: 4.47 = AA |
Beneish M -3.54
| DSRI: 0.78 (Receivables 238.7m/269.9m, Revenue 1.17b/1.03b) |
| GMI: 0.57 (GM 48.95% / 27.96%) |
| AQI: 1.10 (AQ_t 0.18 / AQ_t-1 0.16) |
| SGI: 1.13 (Revenue 1.17b / 1.03b) |
| TATA: -0.10 (NI 54.2m - CFO 181.3m) / TA 1.28b) |
| Beneish M-Score: -3.54 (Cap -4..+1) = AAA |
What is the price of MBB shares?
Over the past week, the price has changed by -1.17%, over one month by -0.24%, over three months by +10.88% and over the past year by +111.30%.
Is MBB a buy, sell or hold?
What are the forecasts/targets for the MBB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 249 | 17.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 245.1 | 15.6% |
MBB Fundamental Data Overview February 02, 2026
P/E Trailing = 21.6203
P/S = 0.9845
P/B = 1.9064
Revenue TTM = 1.17b EUR
EBIT TTM = 152.7m EUR
EBITDA TTM = 202.9m EUR
Long Term Debt = 32.6m EUR (from longTermDebt, last quarter)
Short Term Debt = 23.3m EUR (from shortTermDebt, last quarter)
Debt = 55.8m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -246.2m EUR (from netDebt column, last quarter)
Enterprise Value = 772.1m EUR (1.18b + Debt 55.8m - CCE 458.8m)
Interest Coverage Ratio = 36.49 (Ebit TTM 152.7m / Interest Expense TTM 4.18m)
EV/FCF = 6.69x (Enterprise Value 772.1m / FCF TTM 115.4m)
FCF Yield = 14.95% (FCF TTM 115.4m / Enterprise Value 772.1m)
FCF Margin = 9.90% (FCF TTM 115.4m / Revenue TTM 1.17b)
Net Margin = 4.64% (Net Income TTM 54.2m / Revenue TTM 1.17b)
Gross Margin = 48.95% ((Revenue TTM 1.17b - Cost of Revenue TTM 595.3m) / Revenue TTM)
Gross Margin QoQ = 51.29% (prev 49.88%)
Tobins Q-Ratio = 0.60 (Enterprise Value 772.1m / Total Assets 1.28b)
Interest Expense / Debt = 1.30% (Interest Expense 724.0k / Debt 55.8m)
Taxrate = 30.01% (15.5m / 51.8m)
NOPAT = 106.9m (EBIT 152.7m * (1 - 30.01%))
Current Ratio = 3.06 (Total Current Assets 800.1m / Total Current Liabilities 261.3m)
Debt / Equity = 0.09 (Debt 55.8m / totalStockholderEquity, last quarter 599.1m)
Debt / EBITDA = -1.21 (Net Debt -246.2m / EBITDA 202.9m)
Debt / FCF = -2.13 (Net Debt -246.2m / FCF TTM 115.4m)
Total Stockholder Equity = 567.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.43% (Net Income 54.2m / Total Assets 1.28b)
RoE = 9.55% (Net Income TTM 54.2m / Total Stockholder Equity 567.2m)
RoCE = 25.46% (EBIT 152.7m / Capital Employed (Equity 567.2m + L.T.Debt 32.6m))
RoIC = 17.54% (NOPAT 106.9m / Invested Capital 609.4m)
WACC = 6.28% (E(1.18b)/V(1.23b) * Re(6.54%) + D(55.8m)/V(1.23b) * Rd(1.30%) * (1-Tc(0.30)))
Discount Rate = 6.54% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.49%
[DCF Debug] Terminal Value 79.81% ; FCFF base≈108.0m ; Y1≈75.4m ; Y5≈38.9m
Fair Price DCF = 251.6 (EV 1.09b - Net Debt -246.2m = Equity 1.34b / Shares 5.32m; r=6.28% [WACC]; 5y FCF grow -35.40% → 2.90% )
[DCF Warning] FCF declining rapidly (-35.40%), DCF may be unreliable
EPS Correlation: 66.25 | EPS CAGR: 41.78% | SUE: N/A | # QB: 0
Revenue Correlation: 78.68 | Revenue CAGR: 16.50% | SUE: 0.28 | # QB: 0
EPS next Year (2026-12-31): EPS=11.11 | Chg30d=+0.317 | Revisions Net=+1 | Growth EPS=+0.5% | Growth Revenue=+4.3%